Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus
Identifieur interne : 001F23 ( Main/Corpus ); précédent : 001F22; suivant : 001F24Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus
Auteurs : Michael W. M. Schüpbach ; Marie Laure Welter ; Anne Marie Bonnet ; Alexis Elbaz ; Brandon R. Grossardt ; Valerie Mesnage ; Jean Luc Houeto ; David Maltête ; Luc Mallet ; Walter A. Rocca ; Alain Mallet ; Yves AgidSource :
- Movement Disorders [ 0885-3185 ] ; 2007-01-15.
English descriptors
Abstract
Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients treated by STN stimulation. Surgery was performed after a median lagtime of 13 years from PD onset at a median age of 57 years. The median follow‐up after surgery was 41 months. Sixteen patients died 8 to 83 months after neurosurgery. Poorer cognitive function was the only predictive factor for mortality (standardized mortality ratio = 2.9; 95% confidence interval [CI], 1.6–4.7; P < 0.0001). Based on a historical comparison of 118 operated patients with 39 nonoperated patients from a different population, survival among operated patients was not better (hazard ratio = 1.2; 95% CI, 0.7–2.1). © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21264
Links to Exploration step
ISTEX:EA1D52661A896691A6735B4F14F20977CE49D3CDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title><author><name sortKey="Schupbach, Michael W M" sort="Schupbach, Michael W M" uniqKey="Schupbach M" first="Michael W. M." last="Schüpbach">Michael W. M. Schüpbach</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Welter, Marie Laure" sort="Welter, Marie Laure" uniqKey="Welter M" first="Marie Laure" last="Welter">Marie Laure Welter</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne Marie" last="Bonnet">Anne Marie Bonnet</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Elbaz, Alexis" sort="Elbaz, Alexis" uniqKey="Elbaz A" first="Alexis" last="Elbaz">Alexis Elbaz</name><affiliation><mods:affiliation>National Institute of Health and Medical Research (INSERM) Unit 708 (former Unit 360), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Grossardt, Brandon R" sort="Grossardt, Brandon R" uniqKey="Grossardt B" first="Brandon R." last="Grossardt">Brandon R. Grossardt</name><affiliation><mods:affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Mesnage, Valerie" sort="Mesnage, Valerie" uniqKey="Mesnage V" first="Valerie" last="Mesnage">Valerie Mesnage</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Houeto, Jean Luc" sort="Houeto, Jean Luc" uniqKey="Houeto J" first="Jean Luc" last="Houeto">Jean Luc Houeto</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Maltete, David" sort="Maltete, David" uniqKey="Maltete D" first="David" last="Maltête">David Maltête</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Mallet, Luc" sort="Mallet, Luc" uniqKey="Mallet L" first="Luc" last="Mallet">Luc Mallet</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Rocca, Walter A" sort="Rocca, Walter A" uniqKey="Rocca W" first="Walter A." last="Rocca">Walter A. Rocca</name><affiliation><mods:affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Mallet, Alain" sort="Mallet, Alain" uniqKey="Mallet A" first="Alain" last="Mallet">Alain Mallet</name><affiliation><mods:affiliation>Department of Biostatistics and Medical Information, Pitié‐Salpêtrière Medical University, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EA1D52661A896691A6735B4F14F20977CE49D3CD</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21264</idno><idno type="url">https://api.istex.fr/document/EA1D52661A896691A6735B4F14F20977CE49D3CD/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title><author><name sortKey="Schupbach, Michael W M" sort="Schupbach, Michael W M" uniqKey="Schupbach M" first="Michael W. M." last="Schüpbach">Michael W. M. Schüpbach</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Welter, Marie Laure" sort="Welter, Marie Laure" uniqKey="Welter M" first="Marie Laure" last="Welter">Marie Laure Welter</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne Marie" last="Bonnet">Anne Marie Bonnet</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Elbaz, Alexis" sort="Elbaz, Alexis" uniqKey="Elbaz A" first="Alexis" last="Elbaz">Alexis Elbaz</name><affiliation><mods:affiliation>National Institute of Health and Medical Research (INSERM) Unit 708 (former Unit 360), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Grossardt, Brandon R" sort="Grossardt, Brandon R" uniqKey="Grossardt B" first="Brandon R." last="Grossardt">Brandon R. Grossardt</name><affiliation><mods:affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Mesnage, Valerie" sort="Mesnage, Valerie" uniqKey="Mesnage V" first="Valerie" last="Mesnage">Valerie Mesnage</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Houeto, Jean Luc" sort="Houeto, Jean Luc" uniqKey="Houeto J" first="Jean Luc" last="Houeto">Jean Luc Houeto</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Maltete, David" sort="Maltete, David" uniqKey="Maltete D" first="David" last="Maltête">David Maltête</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Mallet, Luc" sort="Mallet, Luc" uniqKey="Mallet L" first="Luc" last="Mallet">Luc Mallet</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Rocca, Walter A" sort="Rocca, Walter A" uniqKey="Rocca W" first="Walter A." last="Rocca">Walter A. Rocca</name><affiliation><mods:affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</mods:affiliation></affiliation></author><author><name sortKey="Mallet, Alain" sort="Mallet, Alain" uniqKey="Mallet A" first="Alain" last="Mallet">Alain Mallet</name><affiliation><mods:affiliation>Department of Biostatistics and Medical Information, Pitié‐Salpêtrière Medical University, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01-15">2007-01-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="257">257</biblScope><biblScope unit="page" to="261">261</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">EA1D52661A896691A6735B4F14F20977CE49D3CD</idno><idno type="DOI">10.1002/mds.21264</idno><idno type="ArticleID">MDS21264</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>deep brain stimulation</term><term>mortality</term><term>subthalamic nucleus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients treated by STN stimulation. Surgery was performed after a median lagtime of 13 years from PD onset at a median age of 57 years. The median follow‐up after surgery was 41 months. Sixteen patients died 8 to 83 months after neurosurgery. Poorer cognitive function was the only predictive factor for mortality (standardized mortality ratio = 2.9; 95% confidence interval [CI], 1.6–4.7; P < 0.0001). Based on a historical comparison of 118 operated patients with 39 nonoperated patients from a different population, survival among operated patients was not better (hazard ratio = 1.2; 95% CI, 0.7–2.1). © 2006 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Michael W.M. Schüpbach MD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Marie Laure Welter MD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Anne Marie Bonnet MD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Alexis Elbaz MD, PhD</name><affiliations><json:string>National Institute of Health and Medical Research (INSERM) Unit 708 (former Unit 360), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Brandon R. Grossardt MS</name><affiliations><json:string>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</json:string></affiliations></json:item><json:item><name>Valerie Mesnage MD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Jean Luc Houeto MD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>David Maltête MD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Luc Mallet MD, PhD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Walter A. Rocca MD, MPH</name><affiliations><json:string>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</json:string><json:string>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</json:string></affiliations></json:item><json:item><name>Alain Mallet PhD</name><affiliations><json:string>Department of Biostatistics and Medical Information, Pitié‐Salpêtrière Medical University, Paris, France</json:string></affiliations></json:item><json:item><name>Yves Agid MD, PhD</name><affiliations><json:string>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>mortality</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>deep brain stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>subthalamic nucleus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><articleId><json:string>MDS21264</json:string></articleId><language><json:string>eng</json:string></language><abstract>Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients treated by STN stimulation. Surgery was performed after a median lagtime of 13 years from PD onset at a median age of 57 years. The median follow‐up after surgery was 41 months. Sixteen patients died 8 to 83 months after neurosurgery. Poorer cognitive function was the only predictive factor for mortality (standardized mortality ratio = 2.9; 95% confidence interval [CI], 1.6–4.7; P > 0.0001). Based on a historical comparison of 118 operated patients with 39 nonoperated patients from a different population, survival among operated patients was not better (hazard ratio = 1.2; 95% CI, 0.7–2.1). © 2006 Movement Disorder Society</abstract><qualityIndicators><score>4.957</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>915</abstractCharCount><pdfWordCount>3265</pdfWordCount><pdfCharCount>21262</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>141</abstractWordCount></qualityIndicators><title>Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>5</total><last>261</last><first>257</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21264</json:string></doi><id>EA1D52661A896691A6735B4F14F20977CE49D3CD</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/EA1D52661A896691A6735B4F14F20977CE49D3CD/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/EA1D52661A896691A6735B4F14F20977CE49D3CD/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/EA1D52661A896691A6735B4F14F20977CE49D3CD/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><notesStmt><note>Swiss National Science Foundation</note><note>Swiss Parkinson's Disease Association</note><note>United States National Institutes of Health - No. R01 NS33978;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title><author><persName><forename type="first">Michael W.M.</forename><surname>Schüpbach</surname></persName><roleName type="degree">MD</roleName><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Marie Laure</forename><surname>Welter</surname></persName><roleName type="degree">MD</roleName><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Anne Marie</forename><surname>Bonnet</surname></persName><roleName type="degree">MD</roleName><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Alexis</forename><surname>Elbaz</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>National Institute of Health and Medical Research (INSERM) Unit 708 (former Unit 360), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Brandon R.</forename><surname>Grossardt</surname></persName><roleName type="degree">MS</roleName><affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation></author><author><persName><forename type="first">Valerie</forename><surname>Mesnage</surname></persName><roleName type="degree">MD</roleName><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Jean Luc</forename><surname>Houeto</surname></persName><roleName type="degree">MD</roleName><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">David</forename><surname>Maltête</surname></persName><roleName type="degree">MD</roleName><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Luc</forename><surname>Mallet</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Walter A.</forename><surname>Rocca</surname></persName><roleName type="degree">MD, MPH</roleName><affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation><affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation></author><author><persName><forename type="first">Alain</forename><surname>Mallet</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Biostatistics and Medical Information, Pitié‐Salpêtrière Medical University, Paris, France</affiliation></author><author><persName><forename type="first">Yves</forename><surname>Agid</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, 75013 Paris, France</p></note><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01-15"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="257">257</biblScope><biblScope unit="page" to="261">261</biblScope></imprint></monogr><idno type="istex">EA1D52661A896691A6735B4F14F20977CE49D3CD</idno><idno type="DOI">10.1002/mds.21264</idno><idno type="ArticleID">MDS21264</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients treated by STN stimulation. Surgery was performed after a median lagtime of 13 years from PD onset at a median age of 57 years. The median follow‐up after surgery was 41 months. Sixteen patients died 8 to 83 months after neurosurgery. Poorer cognitive function was the only predictive factor for mortality (standardized mortality ratio = 2.9; 95% confidence interval [CI], 1.6–4.7; P < 0.0001). Based on a historical comparison of 118 operated patients with 39 nonoperated patients from a different population, survival among operated patients was not better (hazard ratio = 1.2; 95% CI, 0.7–2.1). © 2006 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>mortality</term></item><item><term>deep brain stimulation</term></item><item><term>subthalamic nucleus</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-01-18">Received</change><change when="2006-08-16">Registration</change><change when="2007-01-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/EA1D52661A896691A6735B4F14F20977CE49D3CD/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v22:2</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2007-01-15">15 January 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="210" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21264</doi><idGroup><id type="unit" value="MDS21264"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2006 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-01-18"></event><event type="manuscriptRevised" date="2006-07-27"></event><event type="manuscriptAccepted" date="2006-08-16"></event><event type="publishedOnlineEarlyUnpaginated" date="2006-12-05"></event><event type="firstOnline" date="2006-12-05"></event><event type="publishedOnlineFinalForm" date="2007-01-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">257</numbering><numbering type="pageLast">261</numbering></numberingGroup><correspondenceTo>Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, 75013 Paris, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21264.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="28"></count><count type="wordTotal" number="3675"></count></countGroup><titleGroup><title type="main" xml:lang="en">Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title><title type="short" xml:lang="en">Mortality in PD and STN Stimulation</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Michael W.M.</givenNames><familyName>Schüpbach</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Marie Laure</givenNames><familyName>Welter</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anne Marie</givenNames><familyName>Bonnet</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Alexis</givenNames><familyName>Elbaz</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Brandon R.</givenNames><familyName>Grossardt</familyName><degrees>MS</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Valerie</givenNames><familyName>Mesnage</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jean Luc</givenNames><familyName>Houeto</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>David</givenNames><familyName>Maltête</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Luc</givenNames><familyName>Mallet</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>Walter A.</givenNames><familyName>Rocca</familyName><degrees>MD, MPH</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Alain</givenNames><familyName>Mallet</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Yves</givenNames><familyName>Agid</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>agid@ccr.jussieu.fr</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>National Institute of Health and Medical Research (INSERM) Unit 708 (former Unit 360), Hôpital de la Salpêtrière, Paris, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="FR" type="organization"><unparsedAffiliation>Department of Biostatistics and Medical Information, Pitié‐Salpêtrière Medical University, Paris, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">mortality</keyword><keyword xml:id="kwd2">deep brain stimulation</keyword><keyword xml:id="kwd3">subthalamic nucleus</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword></keywordGroup><fundingInfo><fundingAgency>Swiss National Science Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Swiss Parkinson's Disease Association</fundingAgency></fundingInfo><fundingInfo><fundingAgency>United States National Institutes of Health</fundingAgency><fundingNumber>R01 NS33978</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients treated by STN stimulation. Surgery was performed after a median lagtime of 13 years from PD onset at a median age of 57 years. The median follow‐up after surgery was 41 months. Sixteen patients died 8 to 83 months after neurosurgery. Poorer cognitive function was the only predictive factor for mortality (standardized mortality ratio = 2.9; 95% confidence interval [CI], 1.6–4.7; <i>P</i> < 0.0001). Based on a historical comparison of 118 operated patients with 39 nonoperated patients from a different population, survival among operated patients was not better (hazard ratio = 1.2; 95% CI, 0.7–2.1). © 2006 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Mortality in PD and STN Stimulation</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus</title></titleInfo><name type="personal"><namePart type="given">Michael W.M.</namePart><namePart type="family">Schüpbach</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marie Laure</namePart><namePart type="family">Welter</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anne Marie</namePart><namePart type="family">Bonnet</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alexis</namePart><namePart type="family">Elbaz</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>National Institute of Health and Medical Research (INSERM) Unit 708 (former Unit 360), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Brandon R.</namePart><namePart type="family">Grossardt</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Valerie</namePart><namePart type="family">Mesnage</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean Luc</namePart><namePart type="family">Houeto</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Maltête</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Luc</namePart><namePart type="family">Mallet</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Walter A.</namePart><namePart type="family">Rocca</namePart><namePart type="termsOfAddress">MD, MPH</namePart><affiliation>Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation><affiliation>Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alain</namePart><namePart type="family">Mallet</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Biostatistics and Medical Information, Pitié‐Salpêtrière Medical University, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yves</namePart><namePart type="family">Agid</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Centre d'Investigation Clinique, Fédération de Neurologie and National Institute of Health and Medical Research (INSERM) Unit 679 (former Unit 289), Hôpital de la Salpêtrière, Paris, France</affiliation><description>Correspondence: Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 boulevard de l'Hôpital, 75013 Paris, France</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-01-15</dateIssued><dateCaptured encoding="w3cdtf">2006-01-18</dateCaptured><dateValid encoding="w3cdtf">2006-08-16</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">28</extent><extent unit="words">3675</extent></physicalDescription><abstract lang="en">Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients treated by STN stimulation. Surgery was performed after a median lagtime of 13 years from PD onset at a median age of 57 years. The median follow‐up after surgery was 41 months. Sixteen patients died 8 to 83 months after neurosurgery. Poorer cognitive function was the only predictive factor for mortality (standardized mortality ratio = 2.9; 95% confidence interval [CI], 1.6–4.7; P < 0.0001). Based on a historical comparison of 118 operated patients with 39 nonoperated patients from a different population, survival among operated patients was not better (hazard ratio = 1.2; 95% CI, 0.7–2.1). © 2006 Movement Disorder Society</abstract><note type="funding">Swiss National Science Foundation</note><note type="funding">Swiss Parkinson's Disease Association</note><note type="funding">United States National Institutes of Health - No. R01 NS33978; </note><subject lang="en"><genre>Keywords</genre><topic>mortality</topic><topic>deep brain stimulation</topic><topic>subthalamic nucleus</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>257</start><end>261</end><total>5</total></extent></part></relatedItem><identifier type="istex">EA1D52661A896691A6735B4F14F20977CE49D3CD</identifier><identifier type="DOI">10.1002/mds.21264</identifier><identifier type="ArticleID">MDS21264</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001F23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:EA1D52661A896691A6735B4F14F20977CE49D3CD
|texte= Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus
}}
| This area was generated with Dilib version V0.6.23. |  |